Health technology assessment

In September 2020, the National Institute for Health and Care Excellence (NICE) published one new interventional procedure guidance (for transcranial magnetic stimulation for auditory hallucinations), one new medical technologies guidance (Axonics sacral neuromodulation system for treating refractory overactive bladder), one new diagnostic guidance (Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke) and four Medtech innovation briefings (for Novii Wireless Patch System, t:slim X2 insulin pump and others). Also, three clinical guidance documents were updated.

Belgian Health Care Knowledge Center (KCE) initiated the health services research on facilitators and barriers for e-Health adoption by general practitioners. The project has been started in 2017 and is still ongoing.

The Belgian Health Care Knowledge Center (KCE) is conducting research towards a faster, substantiated decision on the reimbursement of innovative medical products. The project started in 2019 and is still being conducted.

On October 14, 2020, the French National Authority for Health (HAS) announced the ongoing update of the submission file guides to support companies who requested reimbursement for medical devices with a system of machine learning (artificial intelligence).

In October 2020, a completed mini-method assessment for the coronary sinus reducer stent (Neovasc) implantation in refractory angina pectoris treatment was published within the New Methods framework. The Oslo University Hospital carried out the evaluation. The technology was recommended for routine use in hospitals.

On October 09, 2020, the National Institute for Health and Care Excellence (NICE) launched a public consultation on proposals for changing how it selects the topics for medicines, medical devices, and diagnostics guidance development. The consultation closes on November 19, 2020.

In September 2020, Swedish Medical Technologies Product (MTP) Council decided to evaluate gene diagnostics for breast cancer within the Orderly introduction framework. Swedish Dental and Pharmaceutical Benefits Agency (TLV) will perform health economic assessments of these tests, including MammaPrint, Oncotype DX, ProSigna, and EndoPredict

On August 31, 2020, Decision Forum decided not to introduce blood-based tests in pregnant women with suspected pre-eclampsia that was evaluated within the New Method framework since 2018

In August 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA26 “Surgical procedures for treatment of obesity.” The key question of the assessment is bariatric surgery for the treatment of adults with obesity.

Earlier in September 2020, the Austrian Institute for Health Technology Assessment (AIHTA) released a synopsis of the ongoing research project “Reimbursement decisions for medical procedures in Austria: An analysis of factors – besides clinical evidence – influencing reimbursement decisions for the hospital benefit catalog 2010-2020.”

On September 03, 2020, National Institute for Health Research (NIHR) opened HTA researcher-led proposal submissions. The proposals can be related to any health problem and should be within the scope of the HTA Program. The closing date is January 6, 2021.

In July 2020, the French National Authority for Health (HAS) issued an update of the methodological guide for the economic evaluation of medical technologies. The main changes aimed to improve the interpretation of the results and the uncertainty, to clarify technical points, and to integrate methodological changes that have occurred since 2011.